Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Over sold, tightly held and great news on the horizon
With new admin. in white house FDA will be held accountable to really deliver new treatments. Exciting year!!
The live cell encapsulation methodology is fundamentally enabling technology for both creating localized cancer cell killing chemical engines & diabetes treatment.
There is a clear positive benefit and not a single immune rejection response has been seen. Being an encapsulated live cell treatment of coarse there will be a very detailed inquiry by the FDA, it may even take two or three meetings, however this team is both experienced and have human trials to show the safety and protocol used previously.
(IMO) Not only will this be an approved trail for treatment of pancreatic cancer, but depending on the new FDA Chief selection, by the six month hard stop there may already be path towards immediate usage.
I had a reasonable position at 7 cents average and then picked by another 2.6 M shares at 2-3 cents during the recent pricing oscillation.
I reviewed a large number of stocks and found only one other of even passing real interest. Play the stock pricing game shell game if you want, but I am keeping my shares of PMCB until Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development has her life's work enabled by cell in a box technology
from the website, (a very good one at that):
EvaMarieBrandtner
Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy. In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company. Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation. This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology. Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes. Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).
Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation. She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings. Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).
Inversion starting; 320 k LII buy: IMO if close +1% short trap in play
GREAT Crystal ball realist !
Best use is in contrarian mode!!!
FYI If you want to lock the MM out, place your shares at 5 dollars sell good for 60 days.
They can't use your shares to short.
See the website!
Not true, the composite data is very strong, and quite public
Level II at close was interesting; big blocks lined up at bottom of 1-month trading band
It is a great website!
The depth and yet clarity of the info provided is excellent. Flat out PMCB's website documents significant and quantitive results from a continuing experimental legacy. The SEM photos of the actual Cell in a Box structure were very impressive.
Level II is very unstable, you may get your wish
Big Pharma doesn't want money, what they want is market control and the future revenue that brings, and they also want to avoid competition.
If they think it is more then a "crap shoot" ( a term I heard back in the day from an Intel lead), they will pay based on future revenues, in my experience about five years worth ...
My experience is that they would want controlling interest to avoid competition, that is why you need two horses in the race for market control, at a minimum you will need to add a zero to your % estimate
Any public knowledge of Big Pharma looking at the Diabetes CIAB possibility alone could easily surpass that number. The TAM is so large, the bio safety so well known, with the key aspect simply that cell in a box works well to keep the immune system away from the cells encapsulated in the inert casing, that the implications on acquisition valuation isn't even worth speculating on. It is hard to even count zeros, at today's float I could easily see market analysis yielding a 5-10 dollar buyout price
I was an integral part of a start up to IPO process in high tech and this market is so large that if, as we did, get two horses in the acquisition race, without question you could push beyond even these valuations
IMO there is no question, this goes on to experimental trial.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190529/
FYI your arguments are both specious and inverted
Level II is a bit out of sync, and shares are trading a bit erratically, I think big money is moving in TBD
I don't know if putting the shares as for sale works, but the tax burden on 3.5 million shares at 50 dollars a share would be horrendous
I just put 3.5 M shares of PMCB @ ETF on sell at 50 dollars/ share with the max 60 day limit, just doubt it makes a difference
Always pick up more when it's oversold..
Right now I have 3.5 M @ 3.36 average, thanks MM game players!
Seems there is an long term accumulation, My expectation is much higher by week's end with significant volatility, especially once it starts touching 8.5-9 We will see....
Once it hits eight cents a whole new market dynamic will ignite, in time if PMCB has two two ponies in the race your $ estimates could be 2-3x short, been there and sometimes these guys will 2-4 x the annual market to ensure they block competition into that particular market. XROS for example...
http://www.lightreading.com/nortel-buys-xros/d/d-id/569812
It is pretty close to perfect storm. BioNewton seems actually slightly conservative in his TAM estimates, there is a huge market, and the bureaucrat types who may have seen The Apprentice and don't want to hear "You're Fired!" are going to do everything they can not to make waves and get phased experiments through the pipeline, exactly what Trump promised at least somewhere along the campaign trail.
Diabetes is a 471 BILLION dollar global market and growing
http://www.healthline.com/diabetesmine/ask-dmine-the-471-billion-dollar-question
Excellent news!
The unconditional language used w.r.t. trials and the principal investigator selection process are also indicators, they are highly confident statements, PMCB are sure they are going ahead and into trials
Exactly what Mick's charts are telling us, and I also posted previously, this stock is very tightly held, it is under accumulation, and when PMCB hits 8 cents it will go up exponentially, anyone naked short are going to really really going regret it.
That is awesome news, agree this company is putting all the right pieces together
Best post yet!
Once it clears a dime you will see plenty of green days
"completely bioinert, illiciting no immune response"
That is the fundamental key, this technology can deliver a plethora of molecular treatments which would normally be either dispersed or disabled and rendered ineffective by the immune system ( diabetes modified cell treatment for example)
Ground floor opportunity: This is going to change lives!
EXACTLY no rejection is KEY. A critical component to the diabetes treatment
All data is clinically important! PMCB technology is proven safe.
Further it is critical for diabetes treatments
shares are tight; new blood would cost whoever is paying for those posts real money. that is the real reason for the assault
"PharmaCyte Biotech Inc. will be doing such studies on a “bio-artificial pancreas” consisting of encapsulated human liver cells that secrete insulin. The approach is based on gene therapy in autoimmune diabetic rats developed over two decades by Ann Simpson, PhD, from the University of Technology in Sydney"
http://blogs.plos.org/dnascience/2016/05/12/gene-therapy-for-type-1-diabetes-preclinical-promise/
Bringing that technology forward to the general population has real potential to dramatically change and improve millions of lives
That is an interesting PMCB Chaikin oscillation
news: diabetes patent notice of allowance
Ball rolling before the bell, that is a bit curious...
Agree, no real shorts, compensation will be stack based; if J&J proper gets involved we all win
This is naked intra day shorting; I seriously doubt anyone is foolish enough to have a real short position on this stock
Advance our product pipeline towards commercialization.”